Clinical Trial
Treatment of grade III and IV astrocytomas with BCNU alone and in combination with VM-26 following surgery and radiation therapy
- PMID: 230893
Item in Clipboard
Clinical Trial
Treatment of grade III and IV astrocytomas with BCNU alone and in combination with VM-26 following surgery and radiation therapy
Cancer Treat Rep.
1979 Nov-Dec.
Abstract
Twenty-one patients with grade III or IV astrocytomas were assigned randomly to receive either BCNU alone or BCNU and VM-26 after surgery and radiation therapy. Patients surviving radiation therapy and receiving single-agent chemotherapy had a median survival of 14 months while those receiving combination chemotherapy had a median survival of 22 months (P greater than 0.05). None of the patients who failed BCNU-only therapy responded to VM-26. Performance status was not affected by either regimen. Computerized tomographic scanning of the brain was useful only in confirming tumor progression. Two patients died from BCNU-related interstitial pulmonary fibrosis.
Similar articles
-
Adjuvant chemotherapy with VM 26 and CCNU after operation and radiotherapy of high-grade supratentorial astrocytomas.Surg Neurol. 1980 Jan;13(1):65-8. Surg Neurol. 1980. PMID: 6244679 Clinical Trial.
-
Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.Cancer Clin Trials. 1979 Spring;2(1):43-8. Cancer Clin Trials. 1979. PMID: 229983 Clinical Trial.
-
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.J Clin Oncol. 2006 Aug 20;24(24):3871-9. doi: 10.1200/JCO.2005.04.6979. J Clin Oncol. 2006. PMID: 16921039 Clinical Trial.
-
Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.J Clin Oncol. 2003 Sep 1;21(17):3276-84. doi: 10.1200/JCO.2003.03.509. J Clin Oncol. 2003. PMID: 12947063 Clinical Trial.
-
High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients.Bone Marrow Transplant. 1996 Jul;18(1):143-9. Bone Marrow Transplant. 1996. PMID: 8832007 Clinical Trial.
Cited by
-
Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.J Neurooncol. 1991 Oct;11(2):85-147. doi: 10.1007/BF02390173. J Neurooncol. 1991. PMID: 1744686 Review. No abstract available.
-
Chemosensitivity of malignant human brain tumors. Preliminary results.J Neurooncol. 1983;1(2):149-66. doi: 10.1007/BF00182961. J Neurooncol. 1983. PMID: 6088712
-
Recurrent brainstem gliomas treated with oral VP-16.J Neurooncol. 1993 Feb;15(2):133-9. doi: 10.1007/BF01053934. J Neurooncol. 1993. PMID: 8509818
-
Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.J Neurooncol. 1990 Feb;8(1):41-5. doi: 10.1007/BF00182085. J Neurooncol. 1990. PMID: 2319289
-
The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme.Acta Neurochir (Wien). 1983;68(3-4):239-51. doi: 10.1007/BF01401182. Acta Neurochir (Wien). 1983. PMID: 6308969